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Subcutaneous adipose tissue stores excess lipids and maintains energy balance. We performed expression quantitative trait locus (eQTL)
analyses by using abdominal subcutaneous adipose tissue of 770 extensively phenotyped participants of the METSIM study. We iden-
tified cis-eQTLs for 12,400 genes at a 1% false-discovery rate. Among an approximately 680 known genome-wide association study
(GWAS) loci for cardio-metabolic traits, we identified 140 coincident cis-eQTLs at 109 GWAS loci, including 93 eQTLs not previously
described. At 49 of these 140 eQTLs, gene expression was nominally associated (p < 0.05) with levels of the GWAS trait. The size of
our dataset enabled identification of five loci associated (p < 5 3 108) with at least five genes located >5 Mb away. These trans-eQTL
signals confirmed and extended the previously reported KLF14-mediated network to 55 target genes, validated the CIITA regulation
of class II MHC genes, and identified ZNF800 as a candidate master regulator. Finally, we observed similar expression-clinical trait cor-
relations of genes associated with GWAS loci in both humans and a panel of genetically diverse mice. These results provide candidate
genes for further investigation of their potential roles in adipose biology and in regulating cardio-metabolic traits.Introduction
Genome-wide association studies (GWASs) have identified
many loci for complex metabolic and cardiovascular traits,
yet the underlying genes and mechanisms by which they
affect disease remain poorly characterized.1,2 The genetic
analysis of gene expression by identification of expression
quantitative trait loci (eQTLs) in relevant tissues has
proven useful to predict candidate genes at GWAS loci
and biological pathways that are perturbed in affected indi-
viduals.3–6 Subcutaneous adipose tissue serves as a buff-
ering system for lipid energy balance, particularly fatty
acids,7,8 and might play a protective role in metabolic
and cardiovascular disease risk.9
Subcutaneous adipose eQTL studies have implicated
genes involved in obesity and metabolic traits.10–13 Recent
GWASs for type 2 diabetes (T2D), cholesterol and triglycer-
ide levels, body mass index, waist-hip ratio, and adiponec-
tin have reported subcutaneous adipose eQTLs that are
coincident with specific GWAS loci.14–17 Similarly, a recent
large GWAS for waist-hip ratio identified loci that were
enriched for genes expressed in subcutaneous adipose
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 2017nuclei.16 Many GWAS loci for these traits do not yet have
clear candidate genes, in part because of the limited statis-
tical power of existing eQTL studies.
trans-eQTL associations between variants and tran-
scripts located far from each other or on different chromo-
somes can identify downstream disease genes, including
those not implicated by GWASs. Identifying these distant
relationships is difficult because of the multiple testing
burden in humans. Studies of natural variation in mice
have identified a number of ‘‘hotspot’’ loci associated
with trans regulation of genes and clinical traits.18,19 One
of the first reported human trans-acting eQTLs involved
the KLF14 transcription factor in adipose tissue.20 The
locus associated with T2D and HDL-cholesterol levels
showed a cis-acting association with expression of KLF14
and ten distal genes.20 Studies of gene expression in circu-
lating monocytes or whole-blood cells have also provided
evidence of trans regulation of gene expression with link-
age to traits relevant to lipid metabolism, type 1 diabetes,
hypertension, celiac disease, and cancer.21,22
In light of the widespread use of mice to help validate
and gain mechanistic understanding of genes in GWAS
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networks of mice and humans are of clear relevance for
studies of common diseases.6 A previous comparison be-
tweenmouse and human adipose transcriptional networks
detected a shared core-network module enriched for genes
involved in the inflammatory and immune response caus-
ally associated with obesity-related traits.10 Recent analysis
of DNase I hypersensitive sites and occupancy profiles of
transcription-factor binding in humans and mice suggests
the preservation of similar regulatory mechanisms for adi-
pose gene expression in both species, and this preservation
could be leveraged to inform disease pathways.23,24
We describe here the analysis of gene expression in 770
subcutaneous adipose samples from Metabolic Syndrome
in Men (METSIM), a study of 10,197 men, 45–73 years of
age, living in the Kuopio area of Finland. Study data
include dense genotypes and extensive metabolic and car-
diovascular traits, such as plasma lipids, inflammatory
markers, glycemic traits, and anthropometric traits.25 We
identified cis-eQTLs at GWAS loci for cardio-metabolic
traits, as well as trans-eQTL hotspots with at least five
distant target genes. We also identified associations of
gene expression with human clinical traits and compared
our results with those of analogous studies in a set of 120
inbred strains of mice.Subjects and Methods
METSIM Study Participants and Sample Characteristics
We analyzed samples from 770 males who are part of the METSIM
study.25 The Ethics Committee of the Northern Savo Hospital Dis-
trict approved this study, and all participants gave written
informed consent. The population-based METSIM study included
10,197 men, aged 45–73 years and randomly selected from the
population register of Kuopio town in eastern Finland (population
95,000). Every participant had a 1 day outpatient visit to the
Clinical Research Unit at the University of Kuopio, including an
interview on the history of previous diseases and current drug
treatment and an evaluation of glucose tolerance and cardiovascu-
lar risk factors. After 12 hr of fasting, a 2 hr oral 75 g glucose toler-
ance test was performed, and the blood samples were drawn at 0,
30, and 120 min. Plasma glucose was measured by enzymatic
hexokinase photometric assay (Konelab Systems reagents; Thermo
Fischer Scientific), and insulin and pro-insulin were determined by
immunoassay (ADVIA Centaur Insulin IRI no. 02230141; Siemens
Medical Solutions Diagnostics). Evaluation of insulin sensitivity
(Matsuda index) and insulin secretion (calculated from area
under the curve between 0 and 30 min of glucose tolerance test
with the formula InsAUC0–30/GlucAUC0–30) have been previously
described.25,26 Plasma levels of lipids were determined via enzy-
matic colorimetric methods (Konelab System reagents, Thermo
Fisher Scientific). Plasma adiponectin was measured with the
Human Adiponectin Elisa Kit (Linco Research), C-reactive protein
with high sensitive assay (Roche Diagnostics GmbH, Mannheim,
Germany), and interleukin 1 receptor agonist with immunoassay
(ELISA, Quantikine DRA00 Human IL-1RA, R&D Systems). Serum
creatinine was measured by the Jaffe kinetic method (Konelab Sys-
tem reagents, Thermo Fisher Scientific) and was used for calcu-
lating the glomerular filtration rate. Height and weight were
measured to the nearest 0.5 cm and 0.1 kg, respectively. WaistThe Americircumference (at the midpoint between the lateral iliac crest and
lowest rib) and hip circumference (at the level of the trochanter
major) were measured to the nearest 0.5 cm. Body composition
was determined by bioelectrical impedance (RJL Systems) in partic-
ipants in the supine position. The characteristics of the study par-
ticipants are shown in Table S1. 770 participants were recruited for
adipose-tissue needle biopsies. 61 participants were diagnosedwith
impaired glucose tolerance, and 27 participants had newly diag-
nosed type 2 diabetes at the time of the tissue collection.Genotyping and Imputation
Genotyping of METSIM samples was performed with the Illumina
HumanOmniExpress BeadChip array and the Illumina Human-
CoreExome at the Center for Inherited Disease Research. Markers
with poor mapping, no founder genotypes, call rate < 95%, devi-
ation from Hardy-Weinberg equilibrium (p < 106), or more than
two alleles were removed from subsequent imputation. We carried
out genotype imputation of the 681,789 directly genotyped vari-
ants that passed quality control by applying the Markov Chain
Haplotyping algorithm (MaCH) and the reference panel from
the Haplotype Reference Consortium (see Web Resources). After
imputation, variants were filtered on the basis of imputation qual-
ity (MaCH r2 > 0.3) and minor-allele frequency (MAF R 0.01).
7,677,146 variants were retained for subsequent analysis.Gene Expression Profiling
Total RNA from METSIM participants was isolated from adipose
tissue via the QIAGEN miRNeasy kit, according to the manufac-
turer’s instructions. RNA integrity numbers (RINs) were assessed
with the Agilent Bioanalyzer 2100 instrument, and 770 samples
with RIN > 7.0 were used for transcriptional profiling. Expression
profiling with the Affymetrix U219 microarray was performed at
the Department of Applied Genomics at Bristol-Myers Squibb ac-
cording to the manufacturer’s protocols. The probe sequences
were re-annotated so that probes that mapped to multiple loca-
tions, contained variants with MAF > 0.01 in the 1000 Genomes
Project European samples, or did not map to known transcripts
on the basis of the RefSeq (version 59) and Ensembl (version 72)
databases were removed; 6,199 probe sets were removed in this
filtering step. For subsequent analyses, we used 43,145 probe sets
that represent 18,155 unique genes. The microarray image data
were processed with the Affymetrix GCOS algorithm via the
robust multiarray average (RMA) method for determination of
the specific hybridizing signal for each gene.PEER Factor Analysis
We applied the probabilistic estimation of expression residuals
(PEER) method27 to infer and account for complex non-genetic
factors affecting gene expression levels. This method is designed
to detect the maximum number of cis-eQTLs. To optimize the dis-
covery of trans-eQTLs within the same analysis, we performed
PEER analysis by examining 10–50 inferred factors (Nk) at incre-
ments of five factors. We then used Matrix eQTL28 to assess the
genetic association with inverse normal-transformed PEER-
processed residuals from RMA-normalized expression data. The
numbers of cis- and trans-eQTLs obtained at different Nk levels
are shown in Table S2. We examined variants on chromosome 7,
including rs4731702 at the known master regulator KLF14,20 to
determine the number of trans-eQTL target genes by using various
numbers of PEER factors. We selected Nk ¼ 35 as a single analysis
to maximize the number of target genes at this locus; thiscan Journal of Human Genetics 100, 428–443, March 2, 2017 429
threshold captured the 94.8% of cis-eQTLs identified with 50 PEER
factors. For downstream eQTL mapping, we used the inverse
normal-transformed PEER-processed residuals after accounting
for 35 factors.eQTL Mapping
We performed eQTLmapping in 770MESTIM individuals by using
both FaST-LMM29 and EPACTS and implementing a linear mixed
model to account for the population structure among the sam-
ples.30 Genotype dosages from all autosomal chromosomes and
expression data that had passed the aforementioned quality-con-
trol measures were used. For FaST-LMM implementation, to
improve power31 when testing all the variants on chromosome
N for association, we constructed the kinship matrix by using
the variants from all other chromosomes besides N. This proced-
ure allowed us to include the variant being tested for association
in the regression equation only once. Results obtained with
FaST-LMM and EPACTS were similar. Results obtained from
EPACTS analysis were used in the identification of coincident
eQTL and GWAS signals. Results from the FaST-LMM analysis are
available on our website.
eQTLs were defined as cis (local) if the peak association was
within 1 Mb on either side of the exon boundaries of the gene
or as trans (distal) if the peak association was at least 5 Mb outside
of the exon boundaries. We used all association p values in the cis
region to estimate the false-discovery rate (FDR-qvalue) by
using the qvalue package in R. Variants with association p values
< 2.46 3 104 corresponding to 1% FDR were considered signifi-
cant. Considering the large number of analyses we performed to
calculate trans-eQTL associations, we used the conservative Bon-
ferroni-corrected p < 1.51 3 1013 (0.05/[7.67 million variants 3
43,145 probe sets]) to identify trans-eQTLs. To detect possible
trans-eQTL hotspots, we report variants that are associated with
at least five genes at a more liberal threshold of p< 53 108. These
hotspots were visualized with Circos-0.66.32 LocusZoom was used
for the regional visualization of eQTL results on the basis of
linkage disequilibrium (LD) ascertained from the 770 METSIM
samples.33Heritability Calculations
Heritability was estimated via a linear mixed model with the
GCTA software.34,35 In this approach, gene expression pheno-
types are assumed to be generated by genetic and environmental
components. The assumption behind the linear-mixed-model
approach is that the covariance of the genetic component of
the phenotypic data is proportional to the kinship or genetic
similarity matrix between the individuals. The analysis provides
estimates of s2u and s
2
e, the variances corresponding to the ge-
netic and environmental components, respectively. The herita-
bility is then the fraction of the variance accounted for by the
genetics
h2 ¼ varðuÞ
varðuÞ þ varðeÞ;
where var(u) and var(e) are, respectively, the genetic and residual
variance components estimated by the restricted-maximum-
likelihood approach using related individuals, and is computed
for each probe set. A standardized kinship matrix, which has a
mean of 1 along the diagonal, is used for these estimates
so that they are consistent with the classical definition of
heritability.36430 The American Journal of Human Genetics 100, 428–443, MarchEvaluation of eQTLs in Another Adipose eQTL Cohort
eQTLs identified in METSIM and MuTHER cohorts37 were
compared in each study reciprocally. Of the ~5 million significant
variant-probe pairs identified in the METSIM study for cis associa-
tions (Table S3), 453,484 had an exact match for the variant in a
corresponding variant-probe pair in theMuTHER study. Amajority
of the genes are represented by multiple probes on the Affymetrix
microarray used in theMETSIM study and the Illuminamicroarray
used in the MuTHER study. Therefore, we required at least 50% of
the variant-probe pairs for a given gene to have the same direction
of effect in both studies at various p value thresholds (p< 53 102
to 5 3 106) in the MuTHER study. Of the 11,053 significant
variant-probe pairs identified in theMETSIM study for trans associ-
ations (Table S3), 2,312 had an exact match for the variant in a
corresponding variant-probe pair in the MuTHER study. We report
the METSIM-detected trans-eQTLs for which the exact variant-
gene pair exists and shows the same direction of effect inMuTHER
at several p value thresholds (p < 5 3 102 to 5 3 106) for which
MuTHER data were available. cis- and trans-eQTLs detected in
the MuTHER study were compared to those in the METSIM study
according to the same criteria.
For the three trans-eQTL hotspots for which the peak variant or
its LD proxy was available in the MuTHER dataset, we were able to
find corresponding variant-probe pairs for 83 of the 106 genes. We
report the variant-gene pairs with the same direction of effect size
at p < 0.05 in the MuTHER study.cis-eQTLs at GWAS Loci
We focused on the GWAS index variants reported to be associated
at genome-wide significance (p < 53 108) with any of 91 cardio-
metabolic diseases and related quantitative traits (Table S4). We
downloaded these variants from the National Human Genome
Research Institute–European Bioinformatics Institute GWAS Cata-
log (September 22, 2014) and included additional variants.16,17We
estimated the number of loci for each trait group on the basis of
the names of ‘‘reported gene(s)’’ and/or ‘‘mapped genes’’ shown
in the catalog. Within the variants available in the METSIM
eQTL data, we initially examined 115 variants at 68 loci for T2D,
114 variants at 68 loci for glycemic traits, 325 variants at 205
loci for obesity and related traits, 410 variants at 213 loci for lipid
traits, 79 variants at 60 loci for metabolic syndrome, and 249 var-
iants at 187 loci for other broadly defined cardiovascular risk traits.
After removing duplicate variants present in at least one disease/
trait group, we further examined the remaining 1,221 GWAS
variants at approximately 680 loci for association with local
gene expression levels.
For significant variant-transcript associations (FDR < 1%), if
multiple probe sets mapped to the same transcript, we retained
the probe sets for which the lead eSNP (the variant that exhibited
the strongest evidence of association with the expression level of
the corresponding transcript) had the largest pairwise LD r2 esti-
mate with the GWAS variant; LD was calculated from the 770
METSIM samples. If two or more highly correlated variants (LD
r2 > 0.8) were associated with the same transcript, we reported
the variant with the largest LD r2 with the lead eSNP. For two var-
iants (pairwise LD r2 ¼ 0.79) associated with different GALNT2
probe sets, we kept the variant exhibiting higher LD r2 with the
GWAS index variant.
We further examined whether each eQTL was coincident with
the GWAS signal. We defined GWAS-coincident eQTLs as loci
with pairwise LD r2 > 0.8 between the GWAS index variant and2, 2017
the lead eSNP. To evaluate association between the GWAS variant
and the lead eQTL variant at each locus, we performed reciprocal
conditional analyses; we tested association between the GWAS
variant and transcript level when the lead eSNP was included in
the model, and vice versa.
For 61 cardio-metabolic traits with publically available GWAS
summary results14,16,17,38–48 (Table S5), we applied the summary-
data-based Mendelian randomization (SMR) method to propose
relevant genes at the GWAS loci.49 We performed a transcrip-
tome-wide association for 61 cardio-metabolic traits and 24,383
probe sets with cis-eQTLs (<1 Mb) and focused on GWAS loci
(p < 5 3 108). Probe sets with pSMR < 2.1 3 10
6 (0.05/24,383
probe sets) were then tested for pleiotropy via heterogeneity in
dependent instruments (HEIDI). Probe sets with pHEIDI R 0.05
were identified as potential gene targets of GWAS loci.
We also quantified the uncertainty in the inference that the cis-
eQTL genes are causally mediating the association between the
GWAS loci with cardio-metabolic traits by using the causal infer-
ence test (CIT).50 We used the GWAS index variants, expression
level of the cis-eQTL genes, and the inverse normalized GWAS trait
measured in METSIM to infer a causal relationship wherein for
gene expression mediates the association between GWAS variant
and trait when pCIT < 0.05.
50Association between Gene Expression Level and
Phenotypic Traits
We conducted regression analyses to evaluate the association be-
tween gene expression and 23 cardio-metabolic-related traits in
up to 770 METSIM individuals. The RMA-normalized expression
levels were inverse normal transformed after age and BMI were ac-
counted for.We used non-PEER-corrected expression levels for this
analysis because correction for PEER factors can remove broadly
acting phenotypic effects on gene expression. Eight of the 35
PEER factors had significant correlation with BMI (jrj ¼ 0.10 to
0.50, p ¼ 2.8 3 103 to 3.5 3 1050). For genes coincident with
GWAS loci, in addition to non-PEER-corrected associations, we
calculated the association between PEER-corrected expression
levels and traits. The 23 phenotypic traits examined included
five obesity-related traits (BMI, waist-hip ratio, waist circumfer-
ence, hip circumference, and fat-free mass), seven glycemic traits
(glucose, insulin, proinsulin, HOMA-b, Hb1Ac, Matsuda index,
and adiponectin), six lipid-related traits (total cholesterol, low-
density lipoprotein cholesterol [LDL-C], high-density lipoprotein
cholesterol [HDL-C], triglycerides, total fatty acids, and free fatty
acids), two inflammatory traits (C-reactive protein and interleukin
1 receptor antagonist), two blood-pressure traits (systolic and dia-
stolic blood pressure, respectively), and one kidney-function trait
(glomerular filtration rate). The phenotypic traits were adjusted
for age and BMI before inverse normal transformation. When
examining the association between gene expression and BMI,
we applied no adjustment for BMI for either the phenotypic trait
(BMI) or gene expression level. We used FDR < 1% (equivalent
p < 6.5 3 104) to define a significant association between gene
expression level and phenotypic-trait level. Genes were clustered
via hierarchical clustering based on Euclidian distance as imple-
mented in the heatmap2 function of the gplots package in R.Mouse Expression and Phenotypic-Trait Data
The mouse studies using the Hybrid Mouse Diversity Panel
(HMDP) have been described previously (GEO: GSE42890).51,52
In brief, mice from 120 strains were obtained from The JacksonThe AmeriLaboratory and were bred at the University of California, Los
Angeles. Mice were maintained on a chow diet (Ralston Purina
Company) until 8 weeks of age, when they were either continued
on a chow diet (n ¼ 185 mice) or given a high-fat, high-sucrose
diet (Research Diets-D12266B) for an additional 8 weeks (n ¼
227 mice). Body composition analysis was performed by nuclear
magnetic resonance with a Bruker Minispec. Retro-orbital blood
was collected under isoflurane anesthesia after mice fasted for
4 hr. Plasma lipids, insulin, glucose, and HOMA-IR were deter-
mined as previously described.52,53 The animal protocol for the
study was approved by the Institutional Care and Use Committee
(IACUC) at the University of California, Los Angeles. Total RNA
from flash-frozen epididymal adipose samples from 228 male
mice was hybridized to Affymetrix HT_MG-430A arrays and
scanned according to standard Affymetrix protocols. To reduce
the chances of spurious association results, we performed RMA
normalization after removing all individual probes with variants
and all probe sets containing eight or more variant-containing
probes, which resulted in 22,416 remaining probe sets. Correla-
tions of non-PEER-corrected expression levels with phenotypic
traits were calculated with the biweight midcorrelation, which is
robust to outliers.54Results
Genetic Variants Associated with Gene Expression in
Subcutaneous Adipose Tissue
To identify genetic loci associated with transcript
abundance in abdominal subcutaneous adipose tissue,
we studied 770 extensively phenotyped men from the
METSIM study. We analyzed ~7.67 million variants and
abundance of 43,145 probe sets corresponding to 18,155
unique genes. The mean narrow-sense heritability, h2, of
the probe sets was 0.27, suggesting significant genetic ef-
fects on adipose gene expression (Figure S1).
eQTL mapping identified cis-eQTLs (<1 Mb) for 12,400
genes at a 1% FDR (p < 2.46 3 104) (Figure S2 and Table
S3). The larger number of adipose eQTLs observed in
comparison to that in previous adipose eQTL studies
might be due to the larger sample size, denser imputation,
and/or analysis of a larger number of transcripts; some
differences might be due to different microarray plat-
forms, statistical methodology, and p value thresholds
(Table S6).10,11,37
30% of the cis-eQTLs discovered in METSIM at p < 5 3
106 showed consistent allelic direction of effect in the
MuTHER study, and 79.1% of the cis-eQTLs reported in
MuTHER at this threshold showed a consistent direction
of effect in METSIM (Table S7).Coincidence of cis-eQTLs and GWAS Loci
Hundreds of GWAS loci have been reported for cardio-
metabolic diseases and related traits.55 Given the value
of identifying candidate genes at GWAS loci and the
observation that many eQTLs are shared across tissues,56
we investigated loci for a broad set of 91 cardio-metabolic
diseases or traits (Table S4). Among the 1,221 GWAS sig-
nals (p < 5 3 108), we detected 944 initial uniquecan Journal of Human Genetics 100, 428–443, March 2, 2017 431
GWAS variant and eQTL gene pairs (FDR< 1%, equivalent
p < 2.4 3 104) (Table S8).
On the basis of pairwise LD r2 > 0.8 between the GWAS
variant and the variant that exhibited the strongest associ-
ation with the gene expression level (lead eSNP), 140
(15%) of the 944 cis-eQTLs appear to be coincident with
the GWAS signals. The coincidence is supported by recip-
rocal conditional analysis: after conditioning was per-
formed on each lead eSNP, no GWAS variant remained
significant (FDR < 1%), and after conditioning on each
GWAS variant, 124 eSNP signals were no longer significant,
and 16 were strongly attenuated (Dlog10(p) of 8.5 to 112 )
(Table S8). Of the 140 cis-eQTLs at GWAS loci, 93 (66.4%)
were not previously reported by large-scale GWASs that
interrogated available cis-eQTLs14–17,38,45,48,57–68 and 50
showed consistent direction of allelic effect at p < 0.05
in the MuTHER study. Table 1 shows 29 eQTLs for glyce-
mic, obesity, and lipid traits at the LD threshold of r2 >
0.9 between the GWAS variant and lead eSNP; three of
these eQTLs were also identified with the SMR method.
The full set of 944 adipose eQTLs at GWAS loci, evidence
of their coincidence with the GWAS signals, and the corre-
sponding p values in the MuTHER study are provided in
Table S8.
To consider potential pleiotropic effects of theGWAS var-
iants on gene expression and cardio-metabolic traits, we
performed two additional tests. We applied the SMR Men-
delian randomizationmethod to loci for 61 traits and iden-
tified 46 genes (pSMR< 2.13 10
6; pHEIDIR 0.05) (Table S9),
19ofwhichwere identifiedvia LD (r2>0.8) andconditional
analyses. The SMR analysis also detected nine genes
(C18orf8, CABLES1, CADM1, CDK6, CENPW, LMOD1,
MFAP2, MT1M, and STARD10) that were not identified via
the conditional analysis approach.
We applied a causal-inference test50 and identified 15
variant-transcript pairs for seven traits that showed evi-
dence of causal mediation (pCIT < 0.05) (Table S10 and
Figure S3). None of the target genes identified by the
causal-inference test overlap with the genes identified by
the SMR analysis.
The coincident GWAS and eQTL signals suggest candi-
date genes that might influence cardio-metabolic risk. For
example, at the ARL15 locus associated with adiponectin
and HDL-C14,38, the GWAS index variant rs6450176 was
associated with expression of FST (p ¼ 3.33 109), located
~500 kb away, and exhibited strong LD (r2¼ 0.99) with the
lead eSNP rs59061738, associated with FST expression (p ¼
1.8 3 109, Figure 1A and Table 1). Reciprocal conditional
analyses provided additional evidence that this eQTL was
coincident with the GWAS signal (pcond ¼ 0.43 for
rs6450176 and 0.17 for rs59061738). FST expression levels
were negatively associated with HDL-C (p ¼ 1.2 3 103)
and adiponectin (p ¼ 6.0 3 106, Figure 1B). Encoded by
FST, the protein follistatin has been shown to promote
adipocyte differentiation and reduce fat mass and insulin
resistance.70,71 The same GWAS variant showed no eQTL
for the nearest gene, ARL15 (p ¼ 0.43), and the expression432 The American Journal of Human Genetics 100, 428–443, Marchlevel of ARL15was not associated with HDL-C (p¼ 0.85) or
adiponectin (p ¼ 0.084). These data suggest that the
associations with the levels of adiponectin and HDL-C at
this GWAS locusmight bemediated at least in part through
the altered expression of FST.
Association between Gene Expression Level and
Phenotypic Traits
We investigated the effects of gene expression levels on
cardio-metabolic risk by evaluating the association
between the expression levels of all 43,145 probe sets
and 23 cardio-metabolic-related traits (Table S11). At
FDR < 1% (equivalent p < 6.5 3 104), we observed
48,365 significant associations between probe set and
trait, and these corresponded to 29,920 gene-trait associa-
tions and 7,643 genes that were associated with 1 to
16 cardio-metabolic traits (Table S12). 10,819 probe sets
(6,064 genes) were associated with BMI, 6,640 probe
sets (3,940 genes) with Matsuda index, and 4,933 probe
sets (3,039 genes) with insulin levels.
We next examined associations between the identified
eQTL genes and cardio-metabolic traits measured in exten-
sively phenotyped participants of the METSIM study.
Among the genes for the 140 GWAS-relevant eQTLs, the
expression levels of 49 were associated with the corre-
sponding GWAS traits at p < 0.05 (Figure 2; also
Figure S4 and Table S8). For example, TBX15 at the
TBX15-WARS2 locus was associated with waist-hip ratio
adjusted for BMI (p ¼ 1.3 3 108) and 12 other traits
(p ¼ 4.3 3 1021 to 2.6 3 104), and expression of
GPR146 at the lipid locus GPR146 was associated with
HDL-C (p ¼ 3.3 3 1013), triglycerides (p ¼ 3.9 3 1013),
and ten other traits (p ¼ 2.3 3 1045 to 6.6 3 105,
Figure 2). These gene expression and trait associations at
GWAS loci further suggest plausible roles of these genes
in mediating variant effects on cardio-metabolic disorders.
Human GWAS eQTL Genes in Mice
Wenext sought additional evidence for the involvement of
GWAS-relevant eQTL genes in regulating cardio-metabolic
traits by comparing results with those from a diverse panel
of 120 inbred mouse strains known as the Hybrid Mouse
Diversity Panel (HMDP).72 In the panel, we identified
microarray probes for 107 of the 140 mouse orthologs
and tested them for association between adipose expres-
sion level and metabolic traits, including plasma lipids, in-
sulin, glucose, and body-fat composition. We observed a
significant correlation between 70 genes and one of the
metabolic traits (p < 5.2 3 105; 0.05/963 tests for nine
traits 3 107 genes) (Figure S5). Of these genes, 25 showed
expression levels correlated with a similar metabolic trait
in the same direction (Table S13). 13.1% of 10,771 orthol-
ogous genes had expression-trait correlations in the same
direction in the adipose tissue of both species for waist-
hip ratio, total cholesterol, insulin, and glucose. For
example, GWAS variants associated with the homeostatic
model of insulin resistance (HOMA-IR) are associated2, 2017
Table 1. Selected Adipose eQTLs Coincident with GWAS Signals for Cardiometabolic Risk
GWAS Variant GWAS Trait GWAS Locus eQTL Gene
GWAS Variant Lead eSNP
LD r2A1/A2 binitial pinitial bcond pcond Lead eSNP A1/A2 binitial pinitial bcond pcond
rs2013208 HDL cholesterol RBM5 RBM6 C/T 0.987 4.4E113 0.120 6.9E01 rs11130233 G/T 0.992 4.7E116 1.099 2.2E04 0.98
rs12051272 adiponectin CDH13 CDH13 T/G 1.370 4.3E80 0.000 2.8E01 rs12051272 T/G 1.370 4.3E80 0.000 2.8E01 1.00
rs6805251 HDL cholesterol GSK3B GSK3B C/T 0.696 1.5E43 0.067 7.4E01 rs334533 C/T 0.718 9.2E47 0.786 1.3E04 0.95
rs8077889 triglycerides MPP3 MPP3 C/A 0.696 9.2E33 0.174 7.4E01 rs55768269 T/C 0.695 5.6E33 0.569 2.8E01 0.99
rs4148008 HDL cholesterol ABCA8 ABCA8 G/C 0.538 5.9E26 0.415 2.1E02 rs1156340 T/C 0.598 1.8E31 1.019 2.5E08 0.92
rs12489828 waist-hip ratio NT5DC2 NT5DC2 G/T 0.503 4.0E24 0.089 7.6E01 rs6778735 T/C 0.510 1.8E24 0.398 1.9E01 0.97
rs138777 total cholesterol TOM1 HMGXB4 A/G 0.495 1.7E22 0.141 8.4E01 rs9306298 T/C 0.498 1.1E22 0.636 3.7E01 0.99
rs2254287 LDL cholesterol B3GALT4 HSD17B8 G/C 0.417 3.5E17 0.000 2.1E01 rs2254287 G/C 0.417 3.5E17 0.000 2.1E01 1.00
rs12679556 waist-hip ratio MSC EYA1 G/T 0.463 1.1E16 0.202 6.2E01 rs4738141 G/A 0.469 3.4E17 0.677 9.7E02 0.98
rs12748152 HDL cholesterol NR0B2-PIGV PIGV T/C 0.698 4.0E14 0.054 8.5E01 rs6656815 A/G 0.732 2.7E15 0.687 1.9E02 0.90
rs10919388 waist-hip ratio GORAB PRRX1 C/A 0.448 4.5E14 0.212 3.3E01 rs6427242 G/C 0.448 3.7E14 0.245 2.5E01 0.93
rs8077889 triglycerides MPP3 DUSP3 C/A 0.430 6.6E13 0.000 5.6E01 rs2342310 C/T 0.430 6.6E13 0.000 5.6E01 1.00
rs11136341 LDL cholesterol PLEC1 PLEC G/A 0.358 9.5E13 0.084 6.5E01 rs10107388 C/T 0.379 4.9E14 0.455 1.5E02 0.92
rs2590838 adiponectin GNL3 NEK4 G/A 0.346 8.4E12 0.018 9.9E01 rs35212380 C/G 0.346 7.8E12 0.415 6.7E01 1.00
rs439401 triglycerides APOE-TOMM40 APOE T/C 0.384 2.1E11 0.000 6.7E01 rs439401 T/C 0.384 2.1E11 0.000 6.7E01 1.00
rs181362 HDL cholesterol UBE2L3 YDJC T/C 0.327 7.6E11 0.254 1.3E01 rs11089620 G/C 0.368 3.1E13 0.621 2.3E04 0.91
rs7134375 HDL cholesterol PDE3A PDE3A C/A 0.342 1.6E10 0.000 3.5E01 rs7134375 C/A 0.342 1.6E10 0.000 3.5E01 1.00
rs11869286 HDL cholesterol STARD3 STARD3 G/C 0.333 1.1E09 0.000 9.8E01 rs11869286 G/C 0.333 1.1E09 0.000 9.8E01 1.00
rs9400239 body mass index FOXO3 FOXO3 C/T 0.323 3.0E09 0.008 9.7E01 rs3800228 G/T 0.337 5.9E10 0.350 5.5E02 0.92
rs12748152 HDL cholesterol NR0B2-PIGV ARID1A T/C 0.521 2.2E08 0.091 7.8E01 rs34217609 C/T 0.515 1.1E08 0.388 2.2E01 0.92
rs3812316 triglycerides MLXIPL BCL7B C/G 0.411 6.5E08 0.059 8.2E01 rs799166 C/G 0.431 2.1E08 0.395 1.4E01 0.92
rs4846914 HDL cholesterol GALNT2 GALNT2 G/A 0.267 4.1E07 0.221 4.4E01 rs4631704 C/T 0.279 1.3E07 0.503 8.4E02 0.97
rs12145743 HDL cholesterol PMVK-HDGF RRNAD1 T/G 0.262 7.9E07 0.115 8.1E01 rs3806415 C/T 0.263 7.8E07 0.139 7.7E01 0.99
rs10501320 proinsulin MADD ACP2 G/C 0.309 1.3E06 0.024 9.7E01 rs11039149 A/G 0.310 1.2E06 0.259 6.5E01 0.99
rs6784615 waist-hip ratio NISCH-STAB1 NISCH T/C 0.649 1.6E06 0.000 6.6E01 rs728408 A/G 0.649 1.5E06 0.000 7.4E01 1.00
rs780094 glucose, triglycerides GCKR EMILIN1 T/C 0.240 3.3E06 0.000 7.2E01 rs780094 T/C 0.240 3.3E06 0.000 7.2E01 1.00
rs10761731 triglycerides JMJD1C NRBF2 A/T 0.231 5.8E06 0.000 5.8E02 rs10761739 G/C 0.233 5.2E06 0.000 4.3E02 1.00
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434 The American Journal of Human Genetics 100, 428–443, Marchwith decreased expression level of IRS1 (p ¼ 2.0 3 1050).
IRS1 expression is negatively correlated with HOMA-IR
(r ¼ 0.40, p ¼ 3.0 3 1030) in METSIM and the HMDP
(r ¼ 0.50, p ¼ 1 3 1013) (Figure S6).
The HMDP data support a biological contribution of 25
eQTL genes at GWAS loci; 18 of these genes did not have
significant associations in humans (p > 0.05) but had
significant associations in mice, possibly because of the
heterogeneous environmental effects in humans and
controlled experimental environment in mice (Table
S13). For example, the chromosome 2q35 variants
reported by the GIANT consortium to be associated with
BMI17 span ~300 kb and nine genes. In METSIM, the
BMI risk allele rs492400 was significantly associated with
increased expression of RQCD1 (p ¼ 8.9 3 1043,
Figure 1C), although RQCD1 expression was only nomi-
nally correlated with BMI (r ¼ 0.09, p ¼ 0.01, Figure 1D).
In the HMDP, Rqcd1 expression was more strongly posi-
tively correlated with subcutaneous fat weight (r ¼ 0.45,
p ¼ 1.2 3 1012, Figure 1E), providing further support for
the role of RQCD1 in BMI. Consistent correlation between
gene expression and clinical traits in mice for cis-regulated
genes at human GWAS loci supports the fruitful use of
mouse models to further understand the roles of candidate
genes for cardio-metabolic traits.
trans-eQTLs
Associations of variants with expression of distant genes in
trans allow the identification of regulatory networks in
adipose tissue. We observed trans-eQTLs at a Bonferroni-
corrected significance threshold (p < 1.51 3 1013) for
90 genes (Table S3). To better identify regulatory networks
in human samples, we searched for variants that were asso-
ciated with at least five distal genes at a more liberal
threshold of p < 5 3 108. These variants were located
on chromosomes 3, 7, 11, and 16 in five independent
loci (pairwise LD r2 ¼ 0) that we termed trans-eQTL hot-
spots (Table S14, Figure 3). Four of the hotspot loci were
associated with local (cis) gene expression at p < 1 3
103 (Figure S7).
40 of the 55 trans-mediated genes at the KLF14 locus
were significantly associated with metabolic phenotypes
at 1% FDR, representing a significant enrichment with
respect to all the genes assayed on the microarray (Chi-
square p value ¼ 8.4 3 106) (Figure S8). The trans-regu-
lated genes were co-expressed with pairwise correlations
of0.48 to 0.67 (p¼ 8.93 104 to 1.63 10100); however,
they were not enriched for known biological pathways ac-
cording to the analysis involving the DAVID database.73
Some of the distal genes have been previously studied in
relation to adipose biology, but their association with the
KLF14 locus was not known. Among the trans-regulated
genes, PLIN5 was associated with 13 of the metabolic phe-
notypes (Figure S8). PLIN5 encodes Perilipin 5, a lipid-
droplet-associated protein that helps maintain a balance
between lipolysis and lipogenesis and has been shown
to play a role in fatty-acid oxidation in adipose tissue.742, 2017
Figure 1. Example Subcutaneous Adipose eQTL Genes at GWAS Loci
(A) The adipose eQTL of FST is coincident with the adiponectin GWAS locus ARL15.69 Regional association of variants with expression
level of FST is shownwith the GWAS variant rs6450176 plotted as the index (purple diamond). LD is colored on the basis of theMETSIM
population.
(B) Association between adiponectin level and FST expression level in METSIM.
(C) The adipose eQTL of RQCD1 is coincident with the USP37 GWAS locus for BMI.17 Regional association of variants with expression
level of RQCD1 is shown with the eSNP rs4674320 (r2 ¼ 1.0 with BMI index SNP rs492400) plotted as the index.
(D and E) Association between (D) BMI and RQCD1 expression level in humans from the METSIM study and (E) body fat and Rqcd1
expression level in mice from the HMDP study.The expanded KLF14-mediated trans network of genes
suggests that these targets might also influence cardio-
metabolic traits.The AmeriVariants located near CIITA (class II, major histocom-
patibility transactivator), which is known to activate the
MHC class II genes at the HLA locus75 (Figure 3B), werecan Journal of Human Genetics 100, 428–443, March 2, 2017 435
Figure 2. Heatmap of Effect Sizes for Significant Associations between Gene Expression Level and Cardio-Metabolic-Trait Levels at
GWAS Loci with Coincident eQTLs
Rows show 23 selected cardio-metabolic traits, and columns show the eQTL genes (and reported GWAS trait at the coincident locus).
Negative values (blue) indicate that increased gene expression level was associated (p < 0.05) with decreased trait level, whereas positive
values (orange) indicate that increased gene expression level was associated with increased trait level.associated with six MHC class II genes (HLA-DPA1, HLA-
DMA, HLA-DPB1, HLA-DOA, HLA-DRA, and HLA-DMB)
located on chromosome 6 and with CD74 on chromo-
some 5. CD74 encodes for a protein that associates with
the class II MHC complex and regulates antigen presenta-
tion.76 The variants were also suggestively associated
with CIITA expression (p ¼ 1.0 3 103, Figure S7), suggest-
ing that variation in its expressionmight be responsible for
the trans-eQTL signals. Our eQTL results captured the
known biology of CIITA regulation of MHC class II genes.
Further, expression of CIITA and the seven trans-mediated
genes was significantly associated with 14 of the metabolic
traits (jbj¼ 0.12 to 0.37, p¼ 6.43 104 to 7.73 1026), sug-
gesting a role for this network of genes in adipose tissue
(Figure S8).
The second largest trans-eQTL hotspot was located on
chromosome 3 and was associated with the expression of
44 genes (Figure 3B). This locus has been reported in other
tissues, including liver and omental fat,77 but the target
genes identified in our study do not overlap with the pre-
vious ones, suggesting a unique trans-regulatory network
in subcutaneous adipose tissue.11 Variants in this locus436 The American Journal of Human Genetics 100, 428–443, Marchshowed the strongest local association with the expression
of SLC25A38, located ~1 Mb away (p ¼ 1.7 3 107,
Figure S7). Missense mutations in SLC25A38, which en-
codes a mitochondrial solute carrier, lead to congenital
sideroblastic anemia characterized by defective erythropoi-
esis and mitochondrial iron overload.78 The function of
SLC25A38 in adipose tissue remains unclear. The signal
observed at this locus might represent cell types other
than adipocytes in light of the cellular heterogeneity of ad-
ipose tissue. The adipose expression level of SLC25A38 was
nominally associated with 24 of the trans-mediated genes
(jbj ¼ 0.07 to 0.29, p ¼ 6.8 3 1016 to 4.7 3 102) and
with 14 cardio-metabolic-related traits (jbj ¼ 0.08 to 0.33,
p ¼ 6.7 3 1021 to 3.1 3 102) (Figure S7). For example,
SLC25A38 is negatively associated with BMI in METSIM
participants (b ¼ 0.33, p ¼ 6.7 3 1021). On the basis
of structural similarity with other SLC25 proteins,
SLC25A38 is predicted to transport glycine into the mito-
chondrial matrix for condensation with succinyl-coen-
zyme A to form 5-aminolevulinic acid, which is exported
to the cytoplasm for haem synthesis.79,80 Only a few of
the trans-mediated genes have been shown to play2, 2017
Figure 3. trans-eQTL Hotspots in Subcutaenous Adipose Tissue
(A) KLF14 trans-eQTL hotspot and target genes in subcutaneous adipose tissue. Representation of the location of 55 distal genes for
which expression level is associated with rs12154627 at the KLF14 locus.
(B) Representation of the location of 65 distal genes for which expression level is associated with one of four trans-eQTL hotspots:
SLC25A38 locus (black), ZNF800 locus (blue), CIITA locus (green), and HBB locus (red).
Arrowheads point to the trans-eQTL loci, and curves indicate the associations with the four sets of target genes.important roles in adipocytes. For example, ESRRA encodes
estrogen-related receptor alpha, which modulates the
expression of adipogenesis genes during adipocyte differ-
entiation.81 SPTLC1 encodes one of the subunits of serine
palmitoyltransferase, the key enzyme in sphingolipid
biosynthesis.82 These bioactive lipids are altered with
obesity and can regulate inflammatory gene expression
in adipocytes.83 Another target gene,GOT2, encodes gluta-
mic-oxaloacetic transaminase, which functions in the in-
ner mitochondrial membrane and has been shown to
play a key role in amino acid metabolism.84 Although
the function in adipose of the genes associated with
SLC25A38 variants remains unclear, our results suggest a
metabolic role.
We also observed a trans-eQTL hotspot, located on
chromosome 7 but ~3.3 Mb away from KLF14, associated
with the expression of nine genes. The variants at this
locus were independent from those at KLF14 and had
distinct target genes (Figure 3B). The lead variant,
rs62621812 in ZNF800, encodes a missense change
(p.Pro103Ser) and is also associated with that gene’s
expression level (p¼ 2.83 1016), providing evidence sug-
gesting that this gene regulates the target genes. ZNF800
encodes a C2H2 zinc finger protein and is a putative tran-
scription factor.85 ZNF800 expression level is associated
with theMatsuda Index (b¼ 0.12, p¼ 1.33 103), suggest-
ing a role in insulin sensitivity.
A fifth trans-eQTL, located on chromosome 11, was asso-
ciated with expression of five trans genes. The peak variant,The Amerirs10742583, is located ~2 kb upstream of HBB, which
encodes beta hemoglobin, and is in complete LD (r2 ¼
1.0) with a HBB synonymous variant, rs713040, although
rs10742583 was not associated with the expression level of
any local gene (p < 2.4 3 104). A functional role for HBB
in adipose biology is not clear. Although HBB is distinctly
and highly expressed in whole blood, the trans-mediated
target genes are expressed in a range of tissues.56 This
trans-eQTL signal might reflect cellular heterogeneity,
especially blood cells present in adipose tissue.
To validate these trans-eQTL hotspots, we asked whether
eQTLs were also observed in the MuTHER study. Variant
information was available for three of the loci, near CIITA,
SLC25A38, and KLF14. All seven genes that mapped to the
CIITA locus, 35 of the 44 genes that mapped to the
SLC25A38 locus, and 41 of the 55 genes that mapped to
the KLF14 locus had corresponding probes available in
the MuTHER study. Although only two of the 35 target
genes for the SLC25A38 locus had evidence of association
(FDR < 1%) in the MuTHER study, many KLF14 and CIITA
target genes were replicated (Table S14). For the KLF14
trans-eQTL hotspot, originally described in MuTHER,20
25 of the 41 target genes showed consistent direction of
effect and nominal associations (p < 0.05) in the MuTHER
study, whereas none of the genes showed an opposite
effect. For the CIITA locus, six of the seven target genes
were validated in MuTHER with a consistent direction of
effect (p < 0.05), indicating strong support for these two
trans-eQTL hotspots.can Journal of Human Genetics 100, 428–443, March 2, 2017 437
Discussion
We report an analysis of genetic variants, adipose gene
expression, and cardio-metabolic traits in a deeply pheno-
typed cross-sectional sample of 770 participants in the
METSIM study and compare the results to those of studies
performed in 120 diverse inbred strains of mice. These re-
sults help to prioritize potential target genes at GWAS
loci, and they identify several trans-regulatory networks
associated with metabolic syndrome and its component
traits. In addition, the results reveal concordance between
mice and humans in terms of correlations between gene
expression and traits.
A main challenge with regard to gaining biological in-
sights from genetic associations is to identify which genes
and pathways explain the associations. Systems genetics
aims to address this challenge by integrating genetic vari-
ants with molecular phenotypes to more comprehensively
define the relationship between genotype and phenotype.
Because a large fraction of the variation underlying com-
mon diseases appears to be regulatory,4,86,87 eQTLs that
coincide with GWAS loci can link trait-associated loci
with molecular perturbations. Overall, using reciprocal
conditional analyses, we provided evidence for 140 genes
at 105 loci that may be involved inmetabolic traits (Table 1
and Table S8). This analysis of gene expression in a single
tissue might not be relevant for the mechanisms of some
of the cardio-metabolic traits. Although our analysis pro-
vides indirect evidence of an association, because the coloc-
alization of an eQTL with a disease locus could be coinci-
dental, the cardio-metabolic phenotypes available in the
METSIM cohort provided additional evidence for 49 genes
for which expression level was associated with the relevant
trait. In addition, a subset of the 140 genes was also linked
to GWAS traits via the summary-data-based Mendelian-
randomization and causal-inference tests. Of note, we
limited our analysis to lead eQTL variants and lead GWAS
variants in high pairwise LD (r2 R 0.8). This threshold
might be conservative if the GWAS lead variant imperfectly
tags a causal variant and might underestimate the number
of GWAS loci that are coincident with eQTLs. Consistent
with this possibility, we found evidence of association for
579 genes at 415 loci for which conditioning on the
GWAS variant partially attenuated the eQTL effect (Table
S8). Furthermore, secondary independent associations for
both eQTLs and GWAS signals have been shown to play
an important role in altering the expression of a gene in a
locus;22 however, additional secondary and tertiary eQTL
signals were not separately analyzed in this study. These
genes provide a larger set of possible targets for GWAS loci.
Employing genotype imputation with a dense reference
panel and analyzing 43,145 transcripts on a microarray to
measure expression, we were able to identify more eQTLs
than were identified in other subcutaneous adipose studies
with similar sample sizes.10,11,37 Using these eQTLs, we
implicated 50 genes that were distinct from the initial
locus annotations used as signposts for the GWAS loci438 The American Journal of Human Genetics 100, 428–443, March(Table S8). For example, rs11231693 is associated
with waist-hip ratio adjusted for BMI16 and is located in
the intron of MACROD1. Our results showed a strong
association with the expression level of VEGFB (p ¼
2.2 3 1067), located 140 kb from the variant. For ten
loci, we identified multiple genes associated with the risk
variants. For example, BMI-associated variants in the
INO80E locus17 are also the strongest variants associated
with the expression of five nearby genes: YPEL3, INO80E,
TMEM219, TBX6, and HIRIP3 (p ¼ 1.4 3 108 to 1.8 3
104), suggesting that variation in one or more of these
genes might influence BMI. Finally, at the GCKR, LCAT,
and LDLR genes that harbor common and rare coding
variants that can affect plasma lipid levels, we observed
eQTL effects on nearby genes, including EMILIN1 at the
GCKR locus (p ¼ 3.3 3 106), GFOD2 and NUTF2 at the
LCAT locus (p ¼ 1.9 3 106 and 1.6 3 104, respectively),
and YIPF2 at the LDLR locus (p ¼ 1.5 3 106). Some coin-
cident associations between GWAS variants and eQTLs
might not contribute strongly to trait variation.
Recent studies demonstrated the evolutionary conserva-
tion of regulatory networks that increase susceptibility to
atherosclerosis and other cardio-metabolic traits in dis-
ease-relevant tissues in humans and mice.88 Genetically
diverse mouse populations allow for the control of con-
founding factors, such as environmental exposure that
are difficult to assess in humans. TheHMDPhas also helped
researchers to understand contributions of genetic factors
to cardio-metabolic traits.72 The results of our cross-species
analysis showed consistent association between traits and
the expression of 25 genes in humans and mice, providing
support for further study of these genes in mouse models
(Figure S5 and Table S13). Of course, the possibility exists
that mechanisms might differ between species or that the
wrong tissues are being compared. In addition to priori-
tizing candidate genes, studies of natural variation in
gene expression in mice should be useful in elucidating
mechanisms relating to the gene-by-gene, gene-by-envi-
ronment, and gene-by-sex interactions.51,52,89 For
example, although it is clear that genetic background con-
tributes to weight gain and related traits in response to
dietary challenge,90 the inability to accurately ascertain
environmental factors over a lifetime in humans has
made molecular dissection difficult. In contrast, studies of
natural variation in mice have revealed that gene-by-envi-
ronment interactions can contribute substantially to the
overall variance in traits such as obesity and that the under-
lying genes and pathways can be identified.51,52
Whereas numerous studies have successfully mapped
cis associations, few studies have reported trans-eQTLs
because of small effect sizes, multiple testing thresholds,
and computational burden.22,37,91 These issues are
consistent with the low reciprocal replication rates of
trans-eQTLs identified in MuTHER and METSIM cohorts.
However, in-depth characterization of the architecture of
trans regulation of gene expression is useful in attempting
to understand complex biological mechanisms, as shown2, 2017
by the expanded network of trans-regulated genes at the
KLF14 locus, which has been associated with T2D and
several metabolic traits. The 55 genes that map to this
locus demonstrate the extensive downstream effects of
an individual association signal and provide additional
genes that might influence disease manifestation. The
identification of trans-regulatory networks also offers op-
portunities for understanding fundamental biology. For
example, ZNF800 is a putative transcription factor, and
although little is known about the function of the encoded
protein, our results implicate a novel role for ZNF800 in
adipose biology. In addition, some trans-eQTL associations
might be influenced by the cellular composition of the
adipose tissue; for example, adipose tissue of obese indi-
viduals tends to have higher macrophage content.90,91
Although we failed to observe any association between
the trans-acting loci and expression of macrophage
markers such as ABCG1 and CD68 (data not shown), we
cannot rule out a role for cell-type heterogeneity. We also
observed weaker cis associations compared to trans associ-
ations in the trans-eQTL hotspots. This may be an artifact
of data pre-processing or inaccuracy in measuring low
levels of expression. Future studies involving single-cell an-
alyses might clarify the role of adipose tissue by identifying
cell-type-specific eQTLs. Our study highlights the power of
a systems-genetics approach in dissecting complex traits
and identifying causal genes and pathways.Accession Numbers
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